SCHEMBL8159231

SCHEMBL8159231

CCO[C@@H](CO)c1ccc(Br)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.39
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
PTGS2 P35354 1/20 0.37
CYP1A2 P05177 1/20 0.36
SLC6A4 P31645 3/20 0.36
SLC6A2 P23975 2/20 0.36
CHRM2 P08172 1/20 0.36
HTR1A P08908 1/20 0.36
ADRA2A P08913 1/20 0.36
CHRM1 P11229 1/20 0.36
DRD1 P21728 1/20 0.36
TBXA2R P21731 1/20 0.36
OPRM1 P35372 1/20 0.36
DRD3 P35462 1/20 0.36
SLC6A3 Q01959 1/20 0.36
FFAR1 O14842 4/20 0.35
MEN1 O00255 1/20 0.34
S1PR4 O95977 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28429811 0.84 SLC6A4 (0.38) GAABCHEACHEPTGS2CYP1A2
SCHEMBL5831995 0.82 FFAR1 (0.49) BCHEACHEPTGS2SLC6A4SLC6A2
SCHEMBL2836885 0.82 ESR1 (0.47) CYP1A2SLC6A2CHRM2HTR1ACHRM1
SCHEMBL8171991 0.81 CYP19A1 (0.38) CYP1A2SLC6A4SLC6A2CHRM2HTR1A
SCHEMBL16993614 0.81 FFAR1 (0.50) SLC6A4SLC6A2SLC6A3FFAR1LMNA
SCHEMBL13361411 0.81 FFAR1 (0.35) BCHEACHEPTGS2FFAR1
SCHEMBL27496871 0.81 TSHR (0.41) BCHEACHEPTGS2CYP1A2FFAR1
SCHEMBL23868114 0.80 GSR (0.50) FFAR1LMNA
SCHEMBL8250743 0.80 CYP1A2 (0.38) CYP1A2SLC6A4SLC6A2CHRM2HTR1A
SCHEMBL8168288 0.80 CYP1A2 (0.38) CYP1A2SLC6A4SLC6A2CHRM2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420830-B2 Macrocyclic factor VIIa inhibitors useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-16 US disclosed
US-8420830-B2 Macrocyclic factor VIIa inhibitors useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-16 US disclosed
US-20100113488-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY 2010-05-06 US disclosed
US-20100113488-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY 2010-05-06 US disclosed
WO-2008079836-A2 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113488-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS F12, F7, F5 GAA 2116/4885BCHE 2183/4885ACHE 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.